- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
Détention brevets de la classe C07D 473/34
Brevets de cette classe: 1050
Historique des publications depuis 10 ans
|
91
|
102
|
86
|
76
|
64
|
45
|
57
|
53
|
50
|
23
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Ono Pharmaceutical Co., Ltd. | 422 |
26 |
| Gilead Sciences, Inc. | 2226 |
25 |
| K36 Therapeutics, Inc. | 31 |
23 |
| Novartis AG | 10224 |
22 |
| Intellikine LLC | 41 |
18 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
16 |
| Rhizen Pharmaceuticals AG | 57 |
16 |
| Infinity Pharmaceuticals, Inc. | 96 |
15 |
| Amgen Inc. | 4431 |
14 |
| Univerzita Palackeho V Olomouci | 135 |
14 |
| AstraZeneca AB | 2820 |
13 |
| Epizyme, Inc. | 360 |
13 |
| Sloan-Kettering Institute for Cancer Research | 625 |
13 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3002 |
13 |
| Incyte Corporation | 1066 |
12 |
| Memorial Sloan-Kettering Cancer Center | 2048 |
12 |
| The Scripps Research Institute | 1342 |
12 |
| F. Hoffmann-La Roche AG | 7816 |
11 |
| Gilead Calistoga LLC | 35 |
11 |
| The Regents of the University of California | 20790 |
10 |
| Autres propriétaires | 741 |